n-3 Fatty acid supplementation and proresolving mediators of inflammation

Research output: Contribution to journalLiterature review

31 Citations (Scopus)
78 Downloads (Pure)

Abstract

© 2016 Wolters Kluwer Health, Inc. Purpose of review The review presents recent developments in the identification of specialized proresolving mediators (SPMs) of inflammation following supplementation with n-3 fatty acids in humans. Recent findings A number of reports have measured SPMs in human plasma after n-3 fatty acid supplementation. Although studies have shown some variability in plasma SPM levels, there is strong evidence that a number of resolvins are increased after n-3 fatty acids to concentrations that have been shown to have biological activity. SPM concentrations at the inflammatory site would be expected to be higher than that in blood. SPMs derived from docosapentaenoic acid require further investigation. Summary Resolution of inflammation is an active process with SPM playing a vital role in maintaining homeostasis. Studies in humans are providing evidence to suggest that this may be a relevant mechanism that can be stimulated by n-3 fatty acid supplementation. Further research is now required to determine SPM profiles in patients with different chronic conditions and to examine whether supplementation with n-3 fatty acids affects SPMs in relation to their clinical outcome.
Original languageEnglish
Pages (from-to)26-32
Number of pages7
JournalCurrent Opinion in Lipidology
Volume27
Issue number1
DOIs
Publication statusPublished - Feb 2016

Fingerprint

Inflammation Mediators
Omega-3 Fatty Acids
Homeostasis
Inflammation
Health
Research

Cite this

@article{99f519e95ded49f49b6a0b63bb0e55c4,
title = "n-3 Fatty acid supplementation and proresolving mediators of inflammation",
abstract = "{\circledC} 2016 Wolters Kluwer Health, Inc. Purpose of review The review presents recent developments in the identification of specialized proresolving mediators (SPMs) of inflammation following supplementation with n-3 fatty acids in humans. Recent findings A number of reports have measured SPMs in human plasma after n-3 fatty acid supplementation. Although studies have shown some variability in plasma SPM levels, there is strong evidence that a number of resolvins are increased after n-3 fatty acids to concentrations that have been shown to have biological activity. SPM concentrations at the inflammatory site would be expected to be higher than that in blood. SPMs derived from docosapentaenoic acid require further investigation. Summary Resolution of inflammation is an active process with SPM playing a vital role in maintaining homeostasis. Studies in humans are providing evidence to suggest that this may be a relevant mechanism that can be stimulated by n-3 fatty acid supplementation. Further research is now required to determine SPM profiles in patients with different chronic conditions and to examine whether supplementation with n-3 fatty acids affects SPMs in relation to their clinical outcome.",
author = "Anne Barden and Emilie Mas and Trevor Mori",
year = "2016",
month = "2",
doi = "10.1097/MOL.0000000000000262",
language = "English",
volume = "27",
pages = "26--32",
journal = "Current Opinion in Lipidology",
issn = "0957-9672",
publisher = "Lippincott Williams & Wilkins",
number = "1",

}

n-3 Fatty acid supplementation and proresolving mediators of inflammation. / Barden, Anne; Mas, Emilie; Mori, Trevor.

In: Current Opinion in Lipidology, Vol. 27, No. 1, 02.2016, p. 26-32.

Research output: Contribution to journalLiterature review

TY - JOUR

T1 - n-3 Fatty acid supplementation and proresolving mediators of inflammation

AU - Barden, Anne

AU - Mas, Emilie

AU - Mori, Trevor

PY - 2016/2

Y1 - 2016/2

N2 - © 2016 Wolters Kluwer Health, Inc. Purpose of review The review presents recent developments in the identification of specialized proresolving mediators (SPMs) of inflammation following supplementation with n-3 fatty acids in humans. Recent findings A number of reports have measured SPMs in human plasma after n-3 fatty acid supplementation. Although studies have shown some variability in plasma SPM levels, there is strong evidence that a number of resolvins are increased after n-3 fatty acids to concentrations that have been shown to have biological activity. SPM concentrations at the inflammatory site would be expected to be higher than that in blood. SPMs derived from docosapentaenoic acid require further investigation. Summary Resolution of inflammation is an active process with SPM playing a vital role in maintaining homeostasis. Studies in humans are providing evidence to suggest that this may be a relevant mechanism that can be stimulated by n-3 fatty acid supplementation. Further research is now required to determine SPM profiles in patients with different chronic conditions and to examine whether supplementation with n-3 fatty acids affects SPMs in relation to their clinical outcome.

AB - © 2016 Wolters Kluwer Health, Inc. Purpose of review The review presents recent developments in the identification of specialized proresolving mediators (SPMs) of inflammation following supplementation with n-3 fatty acids in humans. Recent findings A number of reports have measured SPMs in human plasma after n-3 fatty acid supplementation. Although studies have shown some variability in plasma SPM levels, there is strong evidence that a number of resolvins are increased after n-3 fatty acids to concentrations that have been shown to have biological activity. SPM concentrations at the inflammatory site would be expected to be higher than that in blood. SPMs derived from docosapentaenoic acid require further investigation. Summary Resolution of inflammation is an active process with SPM playing a vital role in maintaining homeostasis. Studies in humans are providing evidence to suggest that this may be a relevant mechanism that can be stimulated by n-3 fatty acid supplementation. Further research is now required to determine SPM profiles in patients with different chronic conditions and to examine whether supplementation with n-3 fatty acids affects SPMs in relation to their clinical outcome.

U2 - 10.1097/MOL.0000000000000262

DO - 10.1097/MOL.0000000000000262

M3 - Literature review

VL - 27

SP - 26

EP - 32

JO - Current Opinion in Lipidology

JF - Current Opinion in Lipidology

SN - 0957-9672

IS - 1

ER -